Table 3.
Univariate and multivariate analysis of PCDH17 expression for overall survival in the Chinese cohort
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| Hazard Ratio (95% CI) | P | Hazard Ratio (95% CI) | P | |
| Full cohort | (n = 97) | (n = 97) | ||
| PCDH17 a | 1.65 (1–2.72) | 0.05 | 2.01 (1.19–2.98) | 0.01 |
| Ageb | 3.07 (1.87–5.04) | < 0.0001 | 2.10 (1.18–3.61) | 0.02 |
| WBC countc | 3.14 (1.92–5.14) | < 0.0001 | 2.06 (1.16–3.64) | 0.01 |
| Cytogenetic riskd | 2.04 (1.49–2.78) | < 0.0001 | 1.60 (1.05–2.43) | 0.03 |
| FLT3-ITDe | 0.80 (0.36–1.77) | 0.58 | – | – |
| NPM1 f | 0.97 (0.39–2.43) | 0.95 | – | – |
| CEBPA f | 1.18 (0.53–2.62) | 0.69 | – | – |
| DNMT3A f | 1.66 (0.71–3.89) | 0.24 | – | – |
| IDH2 f | 6.13 (0.8–47) | 0.08 | 5.35 (0.63–45.16) | 0.12 |
| NRAS f | 1.18 (0.37–3.81) | 0.78 | – | – |
| KRAS f | 8.80 (2.53–30.55) | < 0.001 | 5.16 (1.13–23.59) | 0.03 |
| U2AF1 f | 14.43 (1.81–115.4) | 0.01 | 4.99 (0.37–67.94) | 0.23 |
| SRSF2 f | 3.28 (0.78–13.85) | 0.11 | 0.95 (0.12–7.46) | 0.96 |
| SETBP1 f | 0.82 (0.11–5.96) | 0.85 | – | – |
| KIT f | 0.64 (0.16–2.64) | 0.54 | – | – |
| CN-AML | (n = 36) | (n = 36) | ||
|---|---|---|---|---|
| PCDH17 a | 2.58 (1.02–6.52) | 0.04 | 2.95 (1.04–8.32) | 0.04 |
| Ageb | 1.39 (0.61–3.14) | 0.43 | – | – |
| WBC countc | 3.05 (1.34–6.93) | 0.008 | 3.26 (1.35–7.87) | 0.009 |
| FLT3-ITDe | 0.48 (0.14–1.63) | 0.24 | – | – |
| NPM1 f | 0.50 (0.15–1.69) | 0.27 | – | – |
| CEBPA f | 1.19 (0.40–3.50) | 0.76 | – | – |
| DNMT3A f | 1.25 (0.42–3.68) | 0.69 | – | – |
| IDH2 f | 6.37 (0.76–53.48) | 0.09 | 13.30 (1.23–143.32) | 0.03 |
| NRAS f | 3.55 (0.45–27.94) | 0.23 | – | – |
| KRAS f | 6.46 (1.37–30.46) | 0.02 | 9.17 (1.72–48.86) | 0.009 |
| SETBP1 f | 6.37 (0.76–53.48) | 0.09 | 4.52 (0.48–42.10) | 0.19 |
Hazard ratio > 1 or Hazard ratio < 1 indicate a higher or lower risk. Only variables with a univariable P ≤ 0.20 were included in the multivariable models. Mutations such as IDH1 and TP53 were either not analyzed or detected in our cohort, thus they were not included in this analysis
CI confidence interval, WBC white blood cells, CN-AML cytogenetically normal AML, ITD internal tandem duplication
aLow vs high expression
b > 60 vs ≤ 60 years
c ≥ 30 vs < 30 × 109/L
dAdverse vs intermediate vs favorable
ePresent vs absent
fMutated vs wild type